FASTinov initiates commercial activities in Europe
FASTinov today announced the start of commercial activities in Europe. The company will progressively introduce its groundbreaking Antibiotic Susceptibility Testing technology that delivers antibiograms in less than two hours directly from blood cultures.
The first three products in the market are AST kits for bloodstream infections. All have the capability to deliver results in less than 2 hours.
The FASTgrampos AST kit allows for ultra-rapid susceptibility testing for gram positive blood infections, validated for 11 antibiotics. The kit also delivers Minimum inhibitory concentration (MIC) for Vancomycin.
The FASTgramneg AST kit delivers ultra-rapid AST for gram negative bloodstream infections, validated for 13 antibiotics. The kit also detects main mechanisms of resistance such as ESBL, and screens for AmpC and carbapenemases.
The FASTcolistin MIC kit includes several dilutions of colistin to provide Minimum inhibitory concentration (MIC) results on gram negative bacteria (Enterobacterales, Pseudomonas and Acinetobacter).
In the first stage of European commercialization, the company will be presenting its technology to leading hospitals, and will progressively expand operations to several European countries.
“Following the excellent results of our validation studies that demonstrated the excellent accuracy of the test, we proceeded to complete the final operational steps, like production and supply chain, and are now ready to distribute”
For more information and the opportunity to present its ultra-rapid AST technology, FAStinov will be present at the upcoming 32nd European Congress of Clinical Microbiology & Infectious Diseases, ECCMID, in Lisbon, Portugal.
FASTinov has developed ultra-rapid, phenotypic antibiotic susceptibility tests for bloodstream infections that deliver antibiograms in less than 2 hours, based upon patented technologies. The company is based in Porto, Portugal.
- For press inquiries, please contact: email@example.com
Share with friends